Androgen receptor expression in clinically localized prostate cancer: Immunohistochemistry study and literature review

Asian Journal of Andrology

Volumn 10, Issue 6, 2008, Pages 855-863

  Qiu, Yi Qing ^a,b   Leuschner, Ivo ^b   Braun, Peter Martin ^b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PARAFFIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; EPITHELIUM CELL; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STROMA CELL; ADENOCARCINOMA; BIOSYNTHESIS; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PARAFFIN EMBEDDING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 59449092037     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00428.x     Document Type: Article

References (26)

1. Huggin C, Steven RE, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-13.
2. Ding Y, Yuan HQ, Kong F, Hu XY, Ren K, Cai J, et al. Ectopic expression of neurotrophic peptide derived from saposin C increases proliferation and upregulates androgen receptor expression and transcriptional activity in human prostate cancer cells. Asian J Androl 2007; 9(5): 601-9.
3. Altuwaijri S, Wu CC, Niu YJ, Mizokami A, Chang HC, Chang C. Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells. Asian J Androl 2007; 9(2): 181-8.
4. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 1996; 77: 934-40.
5. Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, et al Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001; 51: 452-9.
6. Theodoropoulos VE, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris AC, Patsouris E, et al. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology 2005; 66: 897-902.
7. Miyamoto KK, Mcsherry SA, Dent GA, Sar M, Wilson EM, French FS, et al Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993; 149: 1015-9.
8. Ruizeveld de Winter JA, Trapman J, Brinkmann AO, Boersma WJ, Mulder E, Schroeder FH. Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 1990; 160: 329-32.
9. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, et al Androgen receptor, Ki67, and P53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005; 66: 332-7.
10. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggresseve clinicopathologic features and decreased biochemical recurrence-free survival in prostate. Am J Surg Pathol 2004; 28: 928-34.
11. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, et al Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001; 61: 423-7.
12. Schatzl G, Madersbacher S, Haitel A, Gsur A, Preyer M, Haidinger G, et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312-5.
13. Pertschuk LP, Schaeffer H, Feldman JG, Macchia RJ, Kim YD, Eisenberg K, et al. Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab Invest 1995; 73: 302-5.
14. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Cheng L, Bostwick DG. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. J Urol 1999; 161: 1233-7.
15. Olapade-Olaopa EO, Mackay EH, Taub NA, Sandhu DP, Terry TR, Habib FK. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res 1999; 5: 569-76.
16. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Bostwick DG. Androgen receptor expression in prostatic intraeptithelial neoplasia and cancer. J Urol 1999; 161: 1229-32.
17. Noordzij MA, Bogdanowicz JF, van Krimpen C, van der Kwast TH, van Steenbrugge GJ. The prognostic value of pre-treatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. J Urol 1997; 158: 1880-4.
18. Gaston KE, Kim D, Singh S, Ford OH 3rd, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 2003; 170: 990-3.
19. Ford OH, Gregory CW, Kim D, Smitherman AB, Mohler JL. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003; 170: 1817-21.
20. Wheeler TM, Lebovitz RM. Fresh tissue harvest for research from prostatecomy specimens. Prostate 1994; 25: 274-9.
21. Lessey BA, Castelbaum AJ, Wolf L, Greene W, Paulson M, Meyer WR, et al. Use of integrins to date the endometrium. Fertil Steril 2000; 73: 779-87.
22. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 2004; 10: 33-9.
23. Sadi MV, Barrack ER. Androgen receptors and growth fraction in metastatic prostate cancer as predictors of time to tumour progression after hormonal therapy. Cancer Surv 1991; 11: 195-215.
24. Sadi MV, Barrack ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 1993; 71: 2574-80.
25. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-6.
26. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis. Cancer Res 1994; 54: 4096-102.